📰 Genentech Access News

Genentech Access News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Genentech Access. Real-time updates on events, politics, business and more.

FDA Approves Genentech's Columvi, the First and Only Bispecific Antibody With a Fixed-Duration Treatment for People With Relapsed or Refractory Diffuse Large B-cell Lymphoma | Business

June 16, 2023

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Jun 15, 2023--

South San Francisco United States Krish Patel Loren Kalm Cem Mangir Lindsey Mathias

Source: valdostadailytimes.com

FDA Approves Genentech's Columvi, the First and Only Bispecific Antibody With a Fixed-Duration Treatment for People With Relapsed or Refractory Diffuse Large B-cell Lymphoma

June 16, 2023

- Pivotal study showed durable responses, with a 56% overall response rate, a 43% complete response (remission) rate, and a median duration of response of 1.5 years (18.4 months) - - Given over

United States South San Francisco Bruno Eschli Loren Kalm Lindsey Mathias Levi Garraway

Source: finanznachrichten.de

FDA Approves Genentech's Columvi, the First and Only Bispecific Antibody With a Fixed-Duration Treatment for People With Relapsed or Refractory Diffuse Large B-cell Lymphoma | Region

June 16, 2023

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Jun 15, 2023--

United States South San Francisco Levi Garraway Krish Patel Lindsey Mathias Informationandmedication Guideor

Source: eagletribune.com

Steve E. Krognes Joins Guardant Health Board of Directors

July 7, 2022

07.07.2022 - Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the appointment of Steve E. Krognes to its board of directors. Mr. Krognes is a professional independent board member in the biotech and life science sector. ...

United States Intermune Inc Goldman Sachs Genentech Inc Harvard Business School Master Of Business Administration

Source: wallstreet-online.de

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science

Navigation

Genentech Access News Today

FDA Approves Genentech's Columvi, the First and Only Bispecific Antibody With a Fixed-Duration Treatment for People With Relapsed or Refractory Diffuse Large B-cell Lymphoma | Business

FDA Approves Genentech's Columvi, the First and Only Bispecific Antibody With a Fixed-Duration Treatment for People With Relapsed or Refractory Diffuse Large B-cell Lymphoma

FDA Approves Genentech's Columvi, the First and Only Bispecific Antibody With a Fixed-Duration Treatment for People With Relapsed or Refractory Diffuse Large B-cell Lymphoma | Region

Steve E. Krognes Joins Guardant Health Board of Directors

Explore More Categories